EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

EMA authorises a biosimilar version of bevacizumab (Abevmy) for multiple cancer indications, expanding access to this biologic therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Carcinoma Non-small-cell Lung
• Carcinoma Renal Cell
• Colorectal Neoplasms
• Fallopian Tube Neoplasms
• Ovarian Neoplasms
• Peritoneal Neoplasms
• Uterine Cervical Neoplasms

Drugs mentioned

• Abevmy (bevacizumab)

Snippet

Status: Authorised. Therapeutic area: Colorectal Neoplasms;Breast Neoplasms;Ovarian Neoplasms;Fallopian Tube Neoplasms;Peritoneal Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 07/07/2026